🇺🇸 FDA
Patent

US 11932851

Exon skipping compositions for treating muscular dystrophy

granted A61KA61K31/713A61K47/60

Quick answer

US patent 11932851 (Exon skipping compositions for treating muscular dystrophy) held by Sarepta Therapeutics, Inc. expires Mon Mar 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Sarepta Therapeutics, Inc.
Grant date
Tue Mar 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
6
CPC classes
A61K, A61K31/713, A61K47/60, A61K47/6455, A61P